Medicare recently approved coverage of home telemonitoring for early detection of incident choroidal neovascularization (CNV) among patients with age-related macular degeneration (AMD), but no economic evaluation has yet assessed its cost-effectiveness and budgetary impact.
may be particularly well suited for application to visual health, such as age-related macular degeneration (AMD).
Age-related macular degeneration is the leading cause of blindness in the United States and currently affects more than 11 million Americans.
3, 4 Most patients with AMD have the dry form and usually experience slow or limited vision loss. However, an estimated 2.2 million patients have the wet form of AMD or choroidal neovascularization (CNV), which can cause metamorphopsia (the distortion of the central vision) and can rapidly progress to profound blindness. 5, 6 In the past decade, anti-vascular endothelial growth factor agents have been used to substantially slow the rate of vision loss among patients with CNV and even restore some vision among treated patients. 7 However, early detection of CNV is vital to preserving vision. 7, 8 Choroidal neovascularization is diagnosed through scheduled dilated eye examinations or, more often, patient selfreferral after visual symptoms. 9, 10 However, even patients who self-refer usually only do so after losing substantial vision. Among 6 community-based studies [10] [11] [12] [13] [14] [15] that reported mean or median acuity at the time of CNV diagnosis, all found acuity of 20/80 or worse, with some patients already blind before diagnosis. Clinical experts have argued that the current system of in-office examinations and self-referral is an inadequate method to ensure timely detection of CNV. 16 The Home Monitoring of the Eye (HOME) Study was a National Eye Institute-initiated clinical trial of the ForeseeHome (Notal Vision Ltd) device deployed among a subgroup of the Age-Related Eye Disease Study 2 (AREDS2) study patients. 17 ForeseeHome is a home-based daily visual-field monitoring system intended to allow patients with the dry form of AMD to detect minute changes in vision associated with the onset of CNV before this vision loss is apparent to the patient, triggering an alert to the prescribing physician to facilitate an emergency dilated eye examination. The HOME study found that supplementing standard care with this home telemonitoring system resulted in significantly better visual acuity at CNV diagnosis compared with standard care only. 18 ForseeHome is currently the only device cleared by the US Food and Drug Administration for home monitoring for CNV, and Medicare approved coverage of the device for patients who met the eligibility criteria in December 2015.
The HOME study was designed to measure acuity outcomes at diagnosis but was not designed to measure the longterm outcomes and costs that may be important for consideration of the overall efficacy and cost-effectiveness of this technology. The objective of the current study was to conduct an economic evaluation of the ForeseeHome system using simulation methods and to apply the findings of the HOME study to the US population at high risk for wet-form AMD. We produced estimates of the long-term effects and outcomes of implementing the ForeseeHome system in the Medicare population, including program costs, visual outcomes, costeffectiveness, net societal costs and a 10-year Congressional Budget Office-style nominal budgetary impact analysis.
Methods
Full details of our approach are included in the eAppendix in the Supplement (which includes eTables 1-12 and an eFigure). In brief, we developed a microsimulation model to assess the effects of ForeseeHome monitoring on long-term epidemiologic, economic, and budgetary outcomes. The model tracks 2 identical populations: one comprising individuals using standard care and the other comprising individuals supplementing standard care with the ForeseeHome system. Values for patients' bilateral initial visual acuity, acuity at time of CNV diagnosis, CNV diagnosis rate, and false-positive rate are based on those observed in the HOME study. We assumed that all diagnosed CNV was treated with antivascular endothelial growth factor therapy. Other costs of AMD are based on Medicare claims costs or Medicare fee schedule reimbursement for procedures that occur at frequencies observed in other published studies 17, [19] [20] [21] or the HOME study. Costs of low vision and productivity losses are based on per-person costs attributable to blindness or visual impairment as reported in the Cost of Vision study. Quality-adjusted life-years (QALYs) were calculated using published utility values based on visual acuity in the better-seeing eye, adjusted by age-specific background utility levels. All data were deidentified, and no primary data were collected as part of this analysis. This analysis was deemed exempt because it was not human subjects research by the institutional review board at NORC at the University of Chicago.
Results are presented by initial AMD stage, using the AREDS simplified severity scale, where stages 0 to 4 represent early AMD defined by the cumulative number of risk factors (presence of large drusen or retinal pigment abnormalities) across both eyes, GA represents geographic atrophy, and CNV represents choroidal neovascularization or wet-form AMD. We denote patients with CNV in 1 eye as having CNV1 and with CNV in 2 eyes as having CNV2. Baseline results include patients with
Analyses and Sensitivity Analyses
We performed 3 primary analyses: (1) a cost-effectiveness analysis, (2) a societal net cost analysis, and (3) a Congressional Budget Office-style 10-year nominal federal budgetary impact analysis. The cost-effectiveness analysis was determined as incremental cost-effectiveness ratios (ICERs), equal to the incremental change in the current value of medical, monitoring, and low vision costs divided by incremental QALYs. The QALYs were calculated by assigning utility values based on acuity of the betterseeing eye or the presence of any monocular vision loss. Utility decrements were assigned to patients based on their expected background utility. The societal net cost analysis was calculated as the current lifetime net costs, including monitoring, medical, and low vision costs, and productivity losses. The 10-year budgetary impact analysis estimated the cumulative nominal budgetary cost per patient during the initial 10 years of Medicare coverage of home monitoring. All costs were adjusted to 2016 US dollars using the medical or overall Consumer Price Index. Future costs and QALYs in the cost-effectiveness and societal net cost analysis were discounted to the current year by 3% annually. Costs for the government budgetary analysis are reported in nominal terms during 10 years.
All factors in the model were sampled from their prior distributions for each of 1000 iterations. We report the central 95% of results as the 95% credible interval. We conducted a univariate sensitivity analysis by individually varying each factor over its respective 95% CI or a plausible range. We also included 3 alternative assumption scenarios that could potentially affect real-world outcomes if (1) monitoring resulted in 1 fewer scheduled examinations per year, (2) earlier detection through monitoring avoided a single injection of ranibizumab, or (3) home monitoring outcomes were compared with outcomes in a separate control group represented by baseline CNV diagnosis acuity observed in the Wills Eye Hospital Treat & Extend study. Table 2 reports the expected per-person life-years lived with vision loss for standard care and home monitoring in the baseline population representing patients with stage 3 AMD, stage 4 AMD, and CNV1. Monitoring led to a 10.8% reduction in expected lifeyears lived with blindness, a 4.4% reduction in life-years with moderate impairment, and a 1.4% reduction in mild impairment, expressed per person eligible and qualified for monitoring.
Results
Cost-effectiveness, net societal cost, and 10-year government budgetary impact per person in the baseline population (AMD stage 3, AMD stage 4, and CNV1) are reported in Table 3 . We estimated that monitoring costs totaled $2645 per patient. Monitoring increased other medical costs by $158 to a lifetime total of $78 098 but reduced the lifetime costs of visual impairment and blindness by $1251 to $9225, leading to an increase in net program and medical costs of $1552 per patient over a lifetime. We estimated an increase in QALYs of 0.044 (from 4.317 to 4.361). The incremental cost ($1552) divided by the incremental QALYs (0.044) yields an ICER of $35 663 (95% CI, cost savings to $235 613). Home monitoring reduced lifetime productivity losses by $644 to $6193. Subtracting averted productivity losses from the incremental cost yields a net societal cost (cost benefit) of $907 (95% CI, −$6302 to $2809) per patient monitored. Compared with standard care, Medicare coverage of home monitoring is expected to increase net federal governmental payments by $1312 (95% CI, $222-$2848) per enrollee during the first 10 years of implementation.
Monitoring patients with only CNV1 resulted in cost savings because averted medical and low vision costs exceeded monitoring costs. However, government expenditures would total $851 during 10 years per patient with CNV1 enrolled because government accrues a greater share of costs than benefits from avoided vision loss than patients do, and many potential budgetary savings would not be achieved until after the initial 10 years. Monitoring patients with preadvanced AMD is relatively less costeffective. Monitoring patients with stage 4 AMD results in an ICER of $73 799, whereas monitoring patients with stage 3 AMD results in an ICER of $127 584 per QALY gained.
Univariate Sensitivity Analysis
The results of the univariate sensitivity analysis are shown in the Figure, which depicts the 8 factors that could cause at least a $1000 change in the ICER and 3 alternative assumption scenarios. Among the variation scenarios, results are most sensitive to an assumed ±50% range in the cost of monthly monitoring, followed by the 95% CIs of the costs of blindness. Results were comparatively insensitive to all other factors because variation in no other factors changed the ICER by more than 10%. Results are highly sensitive to the 3 hypothetical alternative assumption scenarios, where avoiding 1 ophthalmologic examination per year, avoiding a single injection of ranibizumab, and comparing home monitoring outcomes to usual care outcomes represented by the Wills Eye Hospital Treat & Extend study each resulted in cost savings for the baseline population.
Discussion
Our study's results suggest that home telemonitoring for patients with AMD at high risk for CNV2, including those with existing CNV1 or with risk factors for CNV2, is likely to be costeffective relative to commonly cited thresholds for costeffectiveness. Using conservative estimates of the potential benefits of the system, we estimated that home monitoring among these patients costs $35 663 per QALY gained, led to a lifetime net societal cost of $907 per patient, and would cost the federal government a total of $1312 per patient during the initial 10 years of Medicare coverage. These findings compare favorably to the oft-cited threshold of $50 000 per QALY. 28 
Research Original Investigation
Economic Evaluation of a Home-Based AMD Monitoring System The HOME study 18 results demonstrated that monitoring patients at high risk for CNV using the ForeseeHome monitoring system results in lower levels of acuity loss at the time of CNV diagnosis. However, the HOME study did not conclusively demonstrate the full benefit of monitoring during a longer time horizon when presumably the lower diagnosis rates observed in the control group would lead to increasing levels of acuity loss over time. The HOME study also did not track costs and outcomes for patients after diagnosis. For this reason, basing results on the HOME study acuity outcomes may underestimate the long-term potential benefits of the program. We test the potential effect of some of these limitations in the alternative scenario results, which are intended to capture plausible real-world effects that were not measured in the HOME study. For example, the 728 patients included in the device monitoring arm of the HOME study underwent nearly 2000 scheduled examinations in the 1.4-year study period, but only 14 of these visits resulted in the detection of CNV. Reducing the mean frequency of scheduled examinations from twice a year to once a year could potentially achieve cost savings, assuming visual outcomes were not substantially affected. Results are also sensitive to potential effects on CNV treatment intensity. If higher acuity values attributable to monitoring avoided even a single injection of ranibizumab or aflibercept, the intervention would be cost saving. Finally, results are even more sensitive to real-world observed acuity outcomes. The HOME study revealed unusually good acuity outcomes even in the control group, possibly because of the short 1.4-year duration and the high rates of scheduled ophthalmologic examinations. Community-based studies typically find far worse levels of acuity at the time of CNV diagnosis. For example, Acharya et al, 29 Fong et al, 10 Olsen et al, 30 and the Wills Eye Hospital Treat & Extend study 11 data reveal that many, if not most, patients who present with CNV are already moderately impaired or blind. When comparing monitoring outcomes with those in an alternative control group based on any of these studies, monitoring is substantially cost saving. Finally, another major limitation of this analysis is that the cost-effectiveness results are largely dependent on patient utility measures used to calculate QALYs. Utility measures are subject to uncertainty, and their use is subject to controversy and misunderstanding. 31 In particular, limited information exists on the utility loss of monocular impairment, which is far more common than bilateral vision loss in our model. Our model assigns QALY losses of 0.0396 for ages 65 to 74 years and 0.036 for ages 75 years and older from any level of monocular impairment or blindness. 25, 26, 32 Because this is assigned as a single threshold, in the model the effect of monitoring patients who only ever progress to monocular vision loss is essentially limited to 1 or 2 years of avoiding this small QALY differential. Our sensitivity results reveal that results are largely insensitive to a 0% to 200% change in the monocular vision utility loss value. However, monitoring substantially reduces the incidence of monocular vision loss.
Conclusions
Although these limitations inhibit our ability to definitively state what the cost-effectiveness of the intervention will be when deployed in the real world, our results indicate that monitoring is likely to be comparatively cost-effective for patients at high risk of progression to bilateral CNV even under conservative assumptions. If patients will not receive high levels of care, such as those observed in the HOME study control group, schedule fewer examinations, or incur lower treatment intensity because of home monitoring, the intervention could potentially be cost saving for the indicated population and may be cost-effective for some lower-risk patients. Before Medicare's decision to provide coverage, use of ForeseeHome was driven by individual patient and family investment decisions to purchase the system based on their health preferences, perceptions of risk, and financial resources. With Medicare coverage, the decision on the part of patients becomes simpler; our results indicate that with 80% Medicare coverage of the device set to begin in 2016, patients and their families may expect to accrue lifetime savings of $586. However, although patients may expect to achieve positive life-term benefits and savings, the program would remain a net cost to government, costing $1312 per enrollee during the initial 10 years of coverage.
Given the large population at risk for CNV and the increased importance of timely CNV diagnosis that has arisen because of the recent adoption of anti-vascular endothelial growth factor therapy for wet-form AMD, the effects of this investment decision are great. In addition, these stakes will only increase in the future as the large increase in the population at risk for AMD in the coming years will rapidly increase the population at risk for blindness from wet-form AMD. The population 90 years and older has the highest prevalence of AMD and is projected to increase 4-fold by 2050. 4, 33 Likewise, the economic burden of vision loss and eye disorders is projected to increase from $139 billion in 2013 to more than $700 billion by 2050 in nominal dollars, with most of these costs attributable to the indirect costs of vision loss. 24, 34 Faced with this explosive growth in the burden and cost of vision disorders, including AMD, the cost of not preventing AMDrelated vision loss may become staggering. Thus, although Medicare coverage of ForeseeHome remains a near-term cost, it could potentially serve as one avenue of investment to mitigate some of the potentially drastic increases in the future costs of vision loss from AMD. Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. With the aging of the US population, the number of persons with age-related macular degeneration (AMD) is expected to rapidly increase in coming decades. Currently, more than 11 million persons are affected by this sight-threatening condition, and the prevalence is expected to double by 2050. 1,2 Rates of other common ocular diseases of aging, such as cataract, glaucoma, and diabetic retinopathy, are also expected to rapidly increase. This projection begs the question of how eye care professionals are going to be able to continue to provide high-quality and timely care to all these patients in the years to come. One potential solution to this dilemma is to look for opportunities to provide care in venues other than the traditional office setting, such as the patient's home. ForeseeHome (Notal Vision LLC) is the first commercially available device to be cleared by the US Food and Drug Administration for independent home monitoring of patients with AMD.
3 It uses preferential hyperacuity perimetry. In a large randomized clinical trial through the Age-Related Eye Disease Study (AREDS) Home Monitoring of the Eye (HOME) study, use of the ForeseeHome device as a supplement to in-office visits led to earlier detection of choroidal neovascularization (CNV) among patients with high-risk nonneovascular AMD, with fewer letters of visual acuity lost by the time of initial CNV diagnosis compared with a control arm of patients who did not receive home monitoring. 4 Although patients in the control arm may have been instructed to use a standard Amsler grid at home, this was left to physician discretion. Given the promising findings from the HOME study, the next logical question is whether the annual cost ($890) for a patient with AMD to use this home monitoring device is worth it. This was the question that Wittenborn and colleagues 5 sought to answer in a study published in this issue of JAMA Ophthalmology. Using data from the HOME study and the Wills Eye Treat and Extend study, they rigorously tallied up all the lifetime medical and nonmedical costs and utilities (which quantify changes in healthrelated quality of life) for patients with AMD, some of whom received home monitoring and others who did not. 5, 6 This enabled them to compare the incremental cost-effectiveness ratio (ICERs) of the home monitoring device use with that of usual care. The researchers found that use of home monitoring for CNV in patients with AMD appears to be more cost-effective than usual care for patients with advanced nonneovascular AMD (AREDS stage 4) or those with CNV in the contralateral eye. Although these study findings seem to be positive at face value, there are several key considerations that may limit the enthusiasm for home monitoring. In their analyses, Wittenborn and colleagues 5 
eAppendix. Economic Analysis of Home AMD Monitoring
To analyze the potential impact of ForeseeHome in the US population with high risk for CNV,
we developed a simulation model to assess the effects of ForeseeHome on health, quality of life, economic and budgetary outcomes. The simulation model allows us to apply the findings of the HOME study to the entire Medicare population at-risk for wet-form AMD, and track the outcomes and effects of AMD including ForeseeHome, other ophthalmologic costs, long-term visual function, costs of low vision, productivity losses and quality adjusted life years, or QALYs.
We include three primary analyses;
1) a cost-effectiveness analysis in which we estimate the incremental costs required to gain a quality adjusted life year (QALY) using a lifetime, societal perspective. This allows the cost per benefit gained of the ForeseeHome system to be directly compared to other interventions that Medicare currently reimburses;
2) a cost-benefit analysis in which the programmatic costs of ForeseeHome are compared to the 
Analysis Methods
We used a Markov model simulation approach in which a population representing patients eligible for the ForeseeHome system are assigned to initial AMD states and progress through AMD states with annual risk of CNV in one or both eyes. 
AMD states and progression
The ForeseeHome system is intended for patients at high risk for CNV, including patients with bilateral risk factors for CNV, or patients who already have CNV in one eye. We use the Age- 
Leading eye
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Study Population
We specified the model to fit the estimated US population aged 65 and older at high risk for CNV because these are the individuals who are anticipated to be eligible and may choose to use the ForeseeHome system. Eligible individuals include those who already have CNV in a single eye (CNV1) and individuals with high bilateral risk of CNV, defined as AREDS simplified severity state 4. [4] Eligibility also requires visual acuity of 20/60 or better in any monitored eye, and the patient must be able to operate the device and establish baseline measures. [5] We exclude patients with prior central geographic atrophy (GA) because an unknown, but likely high proportion would be ineligible for home monitoring due to acuity worse than 20/60. Based on the findings of the HOME study, we assume 78% of individuals in states 3, 4 and CNV1 who attempt to enroll would meet eligibility criteria and undergo monitoring. [5] We assume the patient population who attempt to enroll would reflect the age, sex and race makeup of the total US population with AMD in states 3, 4 and CNV1, with actual number of persons who enroll based on program uptake projections provided by Notal Vision. No published prevalence estimates of the population in AREDS stage or with unilateral CNV exist. We therefore estimated the US population eligible for the program using published estimates of the prevalence of AMD as reported by the Eye Disease Prevalence Research Group (EDPRG), which provides separate prevalence estimates by age group for any AMD, large drusen, GA or CNV, applied to 2013 US Census estimates. [6] We then partitioned the AMD population estimates by stage. To estimate the AREDS state 3 and 4 population, we multiplied the estimated "large drusen" population by the proportion of pre-advanced AMD AREDS patients that were in state 3 and 4 at baseline. To estimate the proportion of CNV patients who had unilateral CNV (CNV1),
we modeled incidence of CNV in one or both eyes, and progression of CNV from unilateral to bilateral using progression rates calculated from AREDS patient data. 
Visual Acuity and Visual Function Classification
Because the overall purpose of the ForeseeHome program is to preserve visual acuity, we use acuity as the primary outcome of our analysis. The model tracks acuity in both eyes of patients using the ETRDS letters system. Visual function is classified as normal, mild impairment, Visual acuity values in the baseline scenario are based directly on those observed in the HOME study, as shown in eTable 3. At model initiation, patients are assigned visual acuity in each eye based on the full sample of acuity measures recorded at the baseline of the HOME study, both for eyes undergoing monitoring as well as any eye not monitoring, which we assume was likely due to existing CNV. The HOME study measured acuity at the time of CNV event; the examination at which CNV was first diagnosed in the study. The model assigns acuity at time of event based on the event acuity measures in the ForeseeHome monitoring and control arms of the HOME study.
Visual acuity values at baseline and at the time of CNV diagnosis are sampled directly from observed values of HOME study patients. HOME study patients could be monitored in one or both eyes. Of 1520 patients in the HOME study, 1078 were monitored in both eyes, 372 were monitored only in the better-seeing eye and 70 were monitored only in the worse-seeing eye.
In each of the 1,000 simulation iterations, we assign a randomly selected value from 0 to 1, and use this to select the closest approximate percentile ranked acuity value observed in the HOME study for the baseline and event acuity measures. Thus, simulated visual acuity measures at the baseline and time of event almost exactly match those values observed in the HOME study.
eTable 3. Visual Acuity Assignment Parameters
In the HOME study, both the control and intervention arms exhibited approximately two examinations per year. Also, the short (average of 1.4 (±0.6) years) duration of the study prevented most patients from losing substantial vision, which could occur over longer time periods. Retrospectively collected real-world data shows substantially worse acuity at time of CNV diagnosis than was observed in the HOME study, in many cases with high proportions of patients presenting already blind. [7] [8] [9] [10] [11] .
Treatment for CNV
At time of CNV event, we assume all patients will initiate anti-VEGF therapy. Treatment efficacy estimates are based on the 2-year outcomes of the CATT Study monthly ranibizumab arm. The CATT study reports the proportion of patients who fell under 5 different ranges of acuity change.
We expressed this outcome as a stepwise function, and then fit a 5-degree polynomial to create a close-fit linear expression of the distribution of acuity outcomes from which to sample in the model.
The SEVEN-UP study is the first to report long-term follow-up of patients undergoing anti-VEGF therapy. [12] Based on pooled outcomes of the ANCHOR, MARINA, and HORIZON study samples, a seven-year follow-up population was reported. The study shows average gains in acuity for two-years following anti-VEGF initiation, followed by a near constant rate of decline for the subsequent 5 years. Based on these results, we reduce acuity beginning 2 years after anti-VEGF therapy begins based on a constant rate of 3.74 ETRDS letters per year. eTable 4 lists the impact of anti-VEGF treatment in the first two years, and the annual decline in acuity beginning in the third year of treatment. 
Examination rates
The HOME study collected detailed data on examination frequency and reason for exam. In both the monitoring and control arms of the study patients underwent relatively frequent scheduled routine exams; 1.94 and 1.95 per year for the monitoring and control arms, respectively. Patients also reported seeing their doctor due to perceived symptoms, at a rate of 0.04 per year. In the monitoring side, patients also could go to their doctor due to a device alert, which occurred at a frequency of 0.24 visits per year. When the ForeseeHome system detects a change in vision, Notal Vision contacts the patients' physicians who in turn may schedule an exam. These visits resulted in either a CNV diagnosis event (device true positive) or did not result in CNV diagnosis (device false positive). In the HOME study, as in actual deployment of this technology, the device can only signal an indication for scheduling an examination. CNV can only be diagnosed in an ensuing ophthalmic examination. We do not consider the possibility of false positive CNV diagnosis at the eye examination, because this is considered the gold-standard diagnostic and presumably such an eventuality would be captured in the net impact of anti-VEGF therapy from the CATT study. Examination rates used in the model from the HOME study are listed in eTable
5.
We included examinations at the rates observed in the HOME study. In the HOME study, the monitoring arm underwent more examinations than the control group, and thus in our analysis the ForeseeHome system results in higher total examination costs.
Examination and AMD management and treatment costs
Medical costs include ophthalmologic visit costs for dry-form AMD and annual costs of wet-form AMD management and anti-VEGF treatment. respectively. [20] Other direct costs of blindness include costs of government assistance programs, low vision aids and adaptations and certain vision rehabilitation costs estimated from federal budgets and the published literature. Indirect costs include productivity losses and long term care. We estimated direct productivity losses associated with moderate or severe difficulty seeing, include losses due to lower employment and reduced wages, using data from the Survey of Income and Program Participation (SIPP). We also include productivity losses attributable to the opportunity costs of informal care givers. [21] We estimated the excess probability of nursing home utilization associated with blindness using data from the Baltimore Eye Study and the National Nursing Home Survey, and applied this utilization to national estimates of nursing home payments by payer. [22] [23] [24] All costs are allocated among three payer categories; government, private insurance, and patient out of pocket. All three categories are included in the net societal cost estimate. Only government costs are included in the government budgetary impact analysis. Tax losses and entitlement programs are included as government costs, but are not included in societal costs other than the inclusion of deadweight losses incurred from economic transfers. Productivity losses are included only in the net-societal cost analysis, and are not included in the costeffectiveness analysis as productivity impacts are assumed to be implicitly captured in the QALY measures, nor are they included in the government budgetary estimate. 
Productivity Costs
We also include productivity costs of low vision as reported by the Cost of Vision report. The utility values used for our analysis are listed in eTable 12. An important aspect of these utility values is that they are based on the
